Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Menarini and Lilly sign comarketing agreement

Aug. 9, 1996

Bifemelane claimed for cerebrovascular disorders treatment

July 26, 1996

Research supports role of testosterone in pathogenesis of stroke

July 26, 1996

Immunex issued U.S. patent for Lerk-7

July 26, 1996

ERT therapy enhances clinical response to tacrine in Alzheimer's patients

July 26, 1996

CP-122638: Pfizer's potential treatment for non-migraine emesis

July 26, 1996

5-HT3/NK1 antagonist combination effective in emesis treatment and prevention

July 26, 1996

Vanderbilt University describes ligands for 5-HT3 receptors

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...